A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis
Clinical Trial Grant
Awarded By
Cabaletta Bio, Inc.
Start Date
July 11, 2024
End Date
July 7, 2042
Awarded By
Cabaletta Bio, Inc.
Start Date
July 11, 2024
End Date
July 7, 2042